“Works in Progress” Seminar
Department of Epidemiology Speaker Series
Trends in antiretroviral therapy use among pregnant persons: 2008–2022
Speaker:
Nedghie Adrien
Postdoctoral Research Fellow
Department of Epidemiology
Harvard T.H. Chan School of Public Health
Abstract: Women comprise nearly a quarter of individuals diagnosed and living with HIV in the United States. Among those individuals living with HIV, 5,000 give birth bear year. Optimal use of antiretroviral therapies during pregnancy is a pillar of the strategies to prevent perinatal transmission of HIV. Using data from pregnancy cohorts nested in the Medicaid Analytic eXtract-Transformed Medicaid Statistical Information System Analytic Files (MAX-TAF) from 2008 to 2018 and the Merative MarketScan Commercial Claims and Encounters Database (MarketScan) from 2008 to 2022, we characterized patterns of antiretroviral use during pregnancy among publicly and privately insured people between 2008 and 2022.
Biography: Nedghie (she/her) is a postdoctoral research fellow in the CAUSALab at the Harvard T.H. Chan School of Public Health (HSPH) supported by the Training Program in Reproductive, Perinatal, and Pediatric (RPP) Life Course Epidemiology (T32HD104612) . Nedghie’s work focuses on evaluating periconceptional diet and medication use, and congenital anomalies. Her other research interests are the application of analytic methods to address mechanisms of systematic bias in observational studies. Nedghie holds a Bachelor of Arts in Clinical Psychology from Tufts University, a Master of Public Health in Global Epidemiology from the Rollins School of Public Health at Emory University, and a PhD in Epidemiology from Boston University’s School of Public Health.
&
First-trimester exposure to newer antiretroviral agents and congenital anomalies in a US cohort
Speaker:
Kelly Fung
Research Scientist
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women’s Hospital & Harvard Medical School
Abstract: Newer antiretroviral medications (ARVs) have been approved to treat HIV in the last ten years, but more data on the potential effects of newer ARVs on the risk of congenital anomalies are needed. We characterized the associations of first-trimester exposure to newer ARV medications with congenital anomalies using a longitudinal cohort of infants born in 2012-2022 to pregnant persons with HIV enrolled in the Surveillance Monitoring for ART Toxicities Study. We found that the odds of congenital anomalies among infants with first-trimester exposure to newer ARVs did not differ substantially from that among infants unexposed to these specific ARVs.
Bio: Kelly Fung is a Research Specialist in the Division of Pharmacoepidemiology and Pharmacoeconomics at the Brigham and Woman’s Hospital and Harvard Medical School. She is a part of the Harvard Program on Perinatal and Pediatric Pharmacoepidemiology and conducts research on the safety of medication exposure during pregnancy using real world data from healthcare utilization databases. Kelly earned a Master of Science in Epidemiology at the Harvard T.H. Chan School of Public Health.